Revolution Medicines' GAAP loss for 3 months of 2022 was $57.647 million, up 55.1% from $37.176 million in the prior year. Revenue declined 25.2% to $7.578 million from $10.131 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept